Diclofenac transdermal first generation - Crescita Therapeutics

Drug Profile

Diclofenac transdermal first generation - Crescita Therapeutics

Alternative Names: Diclofenac transdermal 1.5%; Pennsaid

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nuvo Research
  • Developer Endo International; Nuvo Research
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 20 Aug 2015 Novu Research receives patent allowance for topical foamed formulations including DMSO in USA
  • 31 Jan 2015 Withdrawn for Musculoskeletal pain in USA (Transdermal) prior to January 2015
  • 17 Oct 2014 Diclofenac transdermal first generation is no longer licensed to Mallinkrodt in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top